Tabor Asset Management LP Invests $506,000 in Inhibrx Biosciences, Inc. (NASDAQ:INBX)

Tabor Asset Management LP acquired a new position in shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 36,195 shares of the company's stock, valued at approximately $506,000. Tabor Asset Management LP owned about 0.25% of Inhibrx Biosciences at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of INBX. Bank of New York Mellon Corp acquired a new position in shares of Inhibrx Biosciences in the fourth quarter worth about $792,000. Charles Schwab Investment Management Inc. acquired a new position in Inhibrx Biosciences during the 4th quarter valued at about $503,000. PNC Financial Services Group Inc. bought a new position in Inhibrx Biosciences during the fourth quarter worth about $28,000. Corient Private Wealth LLC bought a new stake in shares of Inhibrx Biosciences in the fourth quarter worth $316,000. Finally, Corebridge Financial Inc. bought a new stake in Inhibrx Biosciences in the fourth quarter valued at approximately $89,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx Biosciences in a research note on Thursday, May 15th.

Inhibrx Biosciences Trading Down 9.5%

Inhibrx Biosciences stock opened at $22.12 on Tuesday. The business has a 50 day moving average price of $15.46 and a two-hundred day moving average price of $13.91. Inhibrx Biosciences, Inc. has a 12 month low of $10.80 and a 12 month high of $24.75. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 1.04. The stock has a market cap of $320.30 million, a price-to-earnings ratio of 0.19 and a beta of -0.04.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.55) by ($0.25). As a group, equities analysts forecast that Inhibrx Biosciences, Inc. will post 104.88 EPS for the current year.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.